Index des mots clés anglais / English key word index – volume 52

0

  A Acid pump inhibitors 612 Adverse Drug Reaction (ADRs) 59-73- 76-78-79-81-82-93-111- 117-143-587-599-610 AIDS 65 Alprazolam 76 Alverin 78 Alzheimer’s disease 477-499-509 Amikacin 219 Aminoguanidine 419 Angiogenesis 399-439 Angiotensin-converting enzyme inhibitor 187-195-599 Anti cancer agents 287 Anti platelet agents 53-399 Anti-oxydative agents 251 Antibiotics 65 Antidepressant 74-117-143 Antihypertensive drugs 187-195-459-535-545-599 Arteriopathy 179-403 Aspirin 53 Assay 227-251-321-327 Atheroma 371-415-423 B Bioavailability 353 Blood pressure measurement 195 C Calcium antagonist 151 Cancerology 287 Cannabis 213 Capillaries 407 Captopril 195 Cardiovascular 9 Case report forms 545 Catecholamines 233 Cell therapy 299 Cell to cell junctions 395 Cellular adhesion 399-429 Citalopram 76 Clinical audit 491 Clinical trials 9-169-179-287-299-487-495 Clozapine 227 Combined antihypertensive therapy 195 Consensus conference 233 Coronary heart disease 37 Cotrimoxazole 73 Cyclosporine 151-313-321-327-329-335-353 Cystic fibrosis 335 Cytochrome P450 607 D Danaparoïd 591 Data bank 207 Data process 13 Data recording 545-579 Decision analysis 535 Depressive disease 79-507 Dextromethorphan 607 Diabetes mellitus 365-371-375-385-387- 389-403-407-415-419-423-447- 453-457-459-461-473 Diuretics 169-195 Dopamine receptors 527 Dopamine receptors agonists 527 Dosage adaptation 219 Drug 307 Drug interactions 74-76-207-608 E Echography 423 Editorial 5-249-475 Elderly 499 Endocrinology 365 Endopeptidase 407 Endothelin 329 Endothelium 371-385-395-439-453 Epidemiology 365-503 Ets1 transcription 439 Evaluation 207-281-287-481- 483-491-495-499-569-579 Experimental pharmacology 375-407-419-429-447-527 F Fluindione 608 Flunarizine 81 Fluoroquinolones 613 Fluvoxamine 74-608 Free radicals 251-387 G Galactorrhea 76 Galenic form 353 Gene therapy 375 Genetic 499 Gingival hyperplasia 73 Good clinical practice 123-299-317-491 Guidelines 579 H Hemodialysis 613 Hemostasis 389 Hepatitis 78-553-610 Herbal medicines 97 HIV protease inhibitor 615 Hormonal therapy 165 Hospital 483-559-569-573 Human haematopoietic progenitors 299 Hydrochlorothiazide 169-195 Hypertension 29-169 Hyponatremia 82 I Immunology 139 Immunossupressor drugs 335 Impotence 473 Individual data 29 Interferon 553 Intermediate outcome 281 Intoxication 155 Intra and inter subject variability 353 Itraconazole 335 L Lipids 389 Lipodystrophia 615 Lisinopril 195 Low molecular weight heparin 47-591 M Macroangiopathy 415-423-461 Medical practice 491 Memory 475-477-481-483- 487-495-499-503-507-509 Memory complaint 487-507 Menopause 165 Mesotherapy 93 Meta-analysis 9-13-19-29-37-47-53 Metabolism 365 Methodology 429-495-535-545 Methotrexate 111-129-133 Micorangiopathy 447-453-457 Microcirculation 429 Moclobemide 82 Models 13-19-59-291-447 Monoclonal antibody 321 Mortality 37 Multicriteria on analysis 535 Mycobacterium avium complex 65 Mycophenolate mofetil 139-341 N Naftidrofuryl 179 Nephrology 457-459 Nephrotoxicity 151-329 Neuroleptic 227 Nicergoline 179 Nifedipine 37 Nilutamide 79 Nitric Oxyde 385-387 Non steroïdal inflammatory drugs 133 Non-insulin dependent diabetic patients 219 O Oesophageal ulcer 587 Omeprazole 612 Overview 251 P Parkinson’s disease 527 Perindopril 187 Pharmaco-epidemiology 579 Pharmacodynamics 143 Pharmacoeconomy 59-553 Pharmacogenetics 74-607 Pharmacokinetics 129-213-291-345-353 Pharmacovigilance 97-105-117-123-143-579-587 Piretanide 169 PK-PD 291 Polypharmacy 573 Population pharmacokinetic 219 Population-based studies 19-29-219 Pregnancy 307-612 Prescription 559-569-573 Proarythmic effects 271 Psychotropics drugs 573 Pubication 123 Q QT 155-271 Quality assurance 545-559-569 Quality control 317 Quality of life 227-553 R Retina 447-453 Retrovirus 439 Rhumatology 111-129-133 Risk factors 111-371-459-599 Risperidone 155 S Schizophrenia 227 Selective serotonin reuptake inhibitors 143 Self blood pressure measurement 187 Self medication 105 Septic shock 233 Sleep disorders 81 Surrogate outcome 281 T Tacrolimus 335-345 Tendon disorder 613 Tetracycline 587 Therapeutic drug monitoring 139-227-313-321-327-341-345 Therapeutic effects 19-29 Therapy utilization studies 559-573 Thrombocytopenia 591 Thromboembolic disease 47-165 Ticlopidine 610 Torsades de pointes 271 Toxicity 387 Toxicology 213 Tramadol 76 Trandolapril 187-599 Transgenic mice 439 Transplant 313-327-341 Transplantation 313-327-335-341 U Unfractionated heparin 47-591 V Vascular wall 371-385-395-403- 415-419-423-429-439-461

Vasodilator 179